Back to Archived Journals » Research and Reports in Endocrine Disorders » Volume 6

Profile of alglucosidase alfa in the treatment of Pompe disease: safety, efficacy, and patient acceptability

Authors Schneider I, Zierz S

Received 12 August 2015

Accepted for publication 19 October 2015

Published 8 January 2016 Volume 2016:6 Pages 1—9

DOI https://doi.org/10.2147/RRED.S72834

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ancuta-Augustina Gheorghisan-Galateanu

Peer reviewer comments 2

Editor who approved publication: Professor Mingzhao Xing


Ilka Schneider, Stephan Zierz

Department of Neurology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

Abstract: Pompe disease, also referred to as glycogenosis type II, is a rare, autosomal recessive disorder that results from the deficiency of the glycogen-degrading enzyme acid α-glucosidase. The classical form presents shortly after birth with muscle hypotonia, cardiac, and respiratory failure resulting in a fatal outcome. The late onset of Pompe disease has a very variable onset and disease presentation that often causes a delayed diagnosis. Until now enzyme replacement therapy with alglucosidase alfa is the only causative therapy option for Pompe patients that can slow down disease progression. However, uncertainty remains about the efficacy regarding survival and quality of life in Pompe patients under this very cost-intensive treatment. This paper provides a systematic review of the literature stressing different aspects of enzyme replacement therapy in infantile and late onset Pompe patients.

Keywords: lysosomal storage disease, glycogenosis type II, acid maltase deficiency, IOPD, LOPD, enzyme replacement therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]